Beam Therapeutics 

Beam Therapeutics 

Yahoo Finance • 3 days ago

Cathie Wood buys $22.8 million of surging tech stock

Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story

Yahoo Finance • 6 days ago

Prime Medicine gains after winning arbitration with Beam Therapeutics

[Genetic engineering] Andy/iStock via Getty Images Prime Medicine (PRME [https://seekingalpha.com/symbol/PRME]) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a... Full story

Yahoo Finance • 17 days ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • last month

Draft FDA guidance could be a boon for gene therapy developers

[Genetic Medicine And DNA Therapy] narvo vexar * The US FDA has issued draft guidance intended to accelerate the development of gene and cell therapies. * The agency hopes the document will enhance the R&D process for the treatments "... Full story

Yahoo Finance • 2 months ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

Key Points CRISPR Therapeutics has an approved product and several gene editing medicines in development. Beam Therapeutics is exploring ways to develop safer gene-editing therapies. One of these stocks is a lot less risky than the other.... Full story

Yahoo Finance • 2 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 2 months ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam logo CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated... Full story

Yahoo Finance • 2 months ago

Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates

A week ago, Beam Therapeutics Inc. (NASDAQ:BEAM) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Revenues of US$32m beat estimates by a substantial 160% margin. Unfortunately, Beam The... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $12.9 million of tumbling tech stock

Cathie Wood, chief of Ark Investment Management, is known for making bold bets on fast-moving tech stocks. Sometimes her trades move just as quickly as the stocks themselves. In the week that began on May 3, Wood sold millions of dollars... Full story

Yahoo Finance • 2 months ago

Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?

Is BEAM a good stock to buy? We came across a bullish thesis on Beam Therapeutics Inc. on r/ValueInvesting by Significant-Pair-275. In this article, we will summarize the bulls’ thesis on BEAM. Beam Therapeutics Inc.'s share was trading at... Full story

Yahoo Finance • 3 months ago

Cathie Wood sells $75M of surging semiconductor stock

Cathie Wood, head of Ark Investment Management, often takes advantage of market swings. That’s what she just did, selling shares of a semiconductor stock after it jumped 25% in a week. Last year, Wood’s flagship Ark Innovation ETF (ARKK)... Full story

Yahoo Finance • 3 months ago

Cathie Wood buys $2.5 million of tumbling megacap stock

Cathie Wood, head of Ark Investment Management, was relatively quiet this week, even as the S&P 500 rallied about 4.5% over the past five days. Wood made no trades on Tuesday, April 14, and Wednesday, April 15, and sold some shares of two... Full story

Yahoo Finance • 3 months ago

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

John M. Evans, CEO of Beam Therapeutics(NASDAQ:BEAM), executed an open-market sale of 30,078 shares on April 1, 2026, valued at approximately $739,000 according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (dire... Full story

Yahoo Finance • 3 months ago

Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM

Cathie Wood’s ARK Invest funds have delivered mixed performance in the recent period, with ARK Space & Defense Innovation ETF (ARKX [https://seekingalpha.com/symbol/ARKX]) up 1.27% and ARK Autonomous Technology & Robotics ETF (ARKQ [https:... Full story

Yahoo Finance • 3 months ago

Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright reaffirmed its Buy rating and $80 price target on Beam Therapeutics Inc. (NASDAQ:BEAM). The rating follows Beam’s... Full story

Yahoo Finance • 3 months ago

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution... Full story

Yahoo Finance • 3 months ago

10 Stocks That Could 10X Over the Next 5 Years

In this article, we will take a look at 10 Stocks That Could 10X Over the Next 5 Years. March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in techn... Full story

Yahoo Finance • 4 months ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam logo Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised... Full story

Yahoo Finance • 5 months ago

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

An updated edition of the Jan. 6, 2026, article. Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pha... Full story

Yahoo Finance • 5 months ago

Walmart downgraded, Etsy upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overw... Full story